BioCryst Pharmaceuticals (BCRX) Stock: Falling Hard After Positive Study Results

BioCryst Pharmaceuticals BCRX Stock News

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is having an overwhelmingly rough start in the premarket hours this morning, leaving many wondering why. The company released what it said was positive clinical data from a Phase 3 trial. However, reading between the lines shows us that things aren’t always what they seem. Today, we’ll talk about: The … Read more

BioCryst Pharmaceuticals (BCRX) Stock: Headed Up On Fast Track Designation

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is having a great start to the trading session this morning after the company announced that its candidate has been granted Fast Track Designation by the FDA. Of course, the news excited investors, sending the stock on a run for the sky. Today, we’ll talk about: The designation; what we’re … Read more

BioCryst Pharmaceuticals (BCRX) Stock: Gaining On Japanese Approval

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) BioCryst Pharmaceuticals is having a strong start to the trading session after announcing that one of its treatments has received regulatory approval in Japan. As a result, investor excitement ensued, leading to gains in the stock and an alert from our partners at Trade Ideas. At the moment (9:41), BCRX … Read more

Biotech Stock News (BCRX) (INCY)

BioCryst Pharmaceuticals (NASDAQ: BCRX) On February 8, 2016 shares of BioCryst Pharmaceuticals fell by more than 71% after the company had announced that it had failed a phase 2 trial. The phase 2 trial known as the OPuS-2 trial recruited a total of 108 patients with Hereditary Angiodema — HAE. HAE is a rare genetic … Read more

BioCryst Pharmaceuticals (BCRX) Stock: Declining On Poor Trial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) BioCryst Pharmaceuticals is having an incredibly hard time in the market at the moment as the result of a recent release of clinical trial results. Unfortunately, a trial has shown that one of the company’s lead candidates is ineffective. Today, we’ll take a look at the trial results, how the … Read more